Pascolizumab

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Pascolizumab ^?
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL-4
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	331243-22-2^N
ATC code	None
UNII	N1IOA09R6A^Y
Chemical data
Formula	?
N (what is this?) (verify)

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.^[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma has been conducted in 2001/2002.^[2]

[edit] References

^ Hart, TK; Blackburn, MN; Brigham-Burke, M; Dede, K; Al-Mahdi, N; Zia-Amirhosseini, P; Cook, RM (2002). "Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma". Clinical and experimental immunology 130 (1): 93–100. doi:10.1046/j.1365-2249.2002.01973.x. PMC 1906490. PMID 12296858. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1906490.
^ ClinicalTrials.gov

Immunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitors: Azathioprine Mycophenolic acid pyrimidine synthesis inhibitors: Leflunomide Teriflunomide antifolate: Methotrexate

Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus Ciclosporin Pimecrolimus Abetimus Gusperimus

TNF-α inhibitor	Thalidomide Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra

mTOR	Sirolimus Everolimus Ridaforolimus Temsirolimus Umirolimus Zotarolimus

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) TNFs (Infliximab Adalimumab Certolizumab pegol Afelimomab Golimumab) Interleukin 5 (Mepolizumab) Immunoglobulin E (Omalizumab) BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab Ustekinumab)

Cellular target	CD3 (Muromonab-CD3 Otelixizumab Teplizumab Visilizumab) CD4 (Clenoliximab Keliximab Zanolimumab) CD11a (Efalizumab) CD18 (Erlizumab) CD20 (Afutuzumab Rituximab Ocrelizumab Pascolizumab) CD23 (Gomiliximab Lumiliximab) CD40 (Teneliximab Toralizumab) CD62L/L-selectin (Aselizumab) CD80 (Galiximab) CD147/Basigin (Gavilimomab) CD154 (Ruplizumab) BLyS (Belimumab) CTLA-4 (Ipilimumab Tremelimumab) CAT (Bertilimumab Lerdelimumab Metelimumab) Integrin (Natalizumab) Interleukin-6 receptor (Tocilizumab) LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab Daclizumab Inolimomab) T-lymphocyte (Zolimomab aritox)

Unsorted	Atorolimumab Cedelizumab Fontolizumab Maslimomab Morolimumab Pexelizumab Reslizumab Rovelizumab Siplizumab Talizumab Telimomab aritox Vapaliximab Vepalimomab

-cept (Fusion)

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	immunosuppression: Adalimumab Atorolimumab Brodalumab Carlumab Fresolimumab Golimumab Lerdelimumab Mavrilimumab Metelimumab Morolimumab Namilumab Nivolumab Oxelumab Sarilumab Sifalimumab Tabalumab Urelumab immune activation: Ipilimumab Tremelimumab other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Itolizumab Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pexelizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab TGN1412^§ non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Briakinumab Canakinumab Fezakinumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wikipedia.org/w/index.php?title=Pascolizumab&oldid=466155878"

Hidden categories:

Personal tools

Log in / create account

Interaction

Toolbox

Print/export